DelayedPDUFA target action date

Deramiocel

Capricor Therapeutics (CAPR)

Marketer take

The FDA advisory committee voted against effectiveness in July 2026 and the date was extended, so DMD teams should treat the outcome as uncertain.

Sponsor company
Capricor Therapeutics (CAPR)
Indication
Duchenne muscular dystrophy (DMD) cardiomyopathy
Therapeutic area
Neurology, Rare disease
Event
PDUFA target action date
Date
Nov 22, 2026
Status
Delayed
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move